Literature DB >> 25667962

TRANSVAC research infrastructure - Results and lessons learned from the European network of vaccine research and development.

Mark J Geels1, Regitze L Thøgersen1, Carlos A Guzman2, Mei Mei Ho3, Frank Verreck4, Nicolas Collin5, James S Robertson3, Samuel J McConkey6, Stefan H E Kaufmann7, Odile Leroy8.   

Abstract

TRANSVAC was a collaborative infrastructure project aimed at enhancing European translational vaccine research and training. The objective of this four year project (2009-2013), funded under the European Commission's (EC) seventh framework programme (FP7), was to support European collaboration in the vaccine field, principally through the provision of transnational access (TNA) to critical vaccine research and development (R&D) infrastructures, as well as by improving and harmonising the services provided by these infrastructures through joint research activities (JRA). The project successfully provided all available services to advance 29 projects and, through engaging all vaccine stakeholders, successfully laid down the blueprint for the implementation of a permanent research infrastructure for early vaccine R&D in Europe.
Copyright © 2015. Published by Elsevier Ltd.

Keywords:  Adjuvants; Animal Models; Biomarkers; European Research Infrastructures; FP7; Harmonisation; Research and Development; Services; Standardisation; Vaccine

Mesh:

Substances:

Year:  2015        PMID: 25667962     DOI: 10.1016/j.vaccine.2015.01.079

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  COVID-19 Pandemic-Revealed Consistencies and Inconsistencies in Healthcare: A Medical and Organizational View.

Authors:  Diana Araja; Uldis Berkis; Modra Murovska
Journal:  Healthcare (Basel)       Date:  2022-05-31

2.  Assay optimisation and technology transfer for multi-site immuno-monitoring in vaccine trials.

Authors:  Steven G Smith; Stephanie A Harris; Iman Satti; Donna Bryan; K Barry Walker; Hazel M Dockrell; Helen McShane; Mei Mei Ho
Journal:  PLoS One       Date:  2017-10-11       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.